Australia's Healthcare Pulse

UK/US security firm Mindgard disclosed on 19–23 March that researchers jailbroke Heidi Health's AI scribe — used in Melbourne-founded Heidi's 800,000+ consultations per week across Australia and inside Monash Health, Queensland Children's Hospital, and Health New Zealand's EDs — with three prompt-level steps (reveal, rebuild, recite). The stripped model ("NEXUS") produced identity-theft instructions, a diagnostic assessment for a cardiac-symptom test patient, and illicit-substance guidance. Heidi confirmed the issue was identified and fixed internally before Mindgard made contact, and that no patient data, backend systems, or other users' sessions were compromised. The TGA confirmed it has opened a review of AI-based digital scribes operating in Australia, including Heidi, noting that "a vendor's attempts to disable therapeutic capabilities" may be insufficient if those measures can be bypassed — raising the prospect of SaMD reclassification.

The TGA opened public consultation on its draft guidance TGA approach to Predetermined Change Control Plans on 10 April 2026, with submissions closing 5 June. The guidance applies to software as a medical device (SaMD), embedded software, and in-vitro diagnostic software, and is explicitly aimed at AI/ML-enabled devices that retrain or update iteratively. It follows the TGA's February 2026 AI SaMD guidance and aligns the Australian regime with the IMDRF PCCP framework, the FDA's 2025 PCCP guidance for AI/ML devices, and the MHRA's 2023 guiding principles.

A Royal Australian College of General Practitioners poll reported by The Guardian Australia on 29 March found approximately 40% of GPs now use some form of AI scribe in daily consultations — a sharp rise from mid-2024 single-digit estimates. The survey coincides with ED doctors in New Zealand estimating up to 10 minutes saved per patient via Heidi, and with Flinders University / SA Pharmacy research in npj Digital Medicine evaluating vision-enabled AI scribes in community pharmacy.

NSW Health Minister Ryan Park announced on 15 April that specially-trained pharmacists will be able to initiate (not just resupply) oral contraceptive prescribing for women aged 18+ from 1 June 2026. The first 5,000 consults will be free under a $4.5M investment; subsequent consults expected at $20–$60. Approximately 70 pharmacists are already trained via a James Cook University graduate certificate, with up to 60 eligible at launch and 773 community pharmacies already part of the resupply scheme. Victoria is expected to roll out an equivalent scheme in July. Patients with clotting history are referred back to GP care.

The industry-weighted average private health insurance premium rise of 4.41% took effect on 1 April 2026 — the highest annual rise since 2017. CHOICE analysis during the month found that HCF Gold-tier hospital cover has risen approximately 25% in some state combinations, and Gold cover across major insurers is up roughly 71% cumulatively over the past five years. Bupa, Medibank, nib and HCF all lifted premiums within the approved range, with Medibank and Bupa positioning for commercial-contract renegotiation ahead of the Federal election cycle.

The Health Legislation Amendment (Modernising My Health Record — Sharing by Default) Act 2024 default-upload provisions commence 1 July 2026, making diagnostic imaging and pathology reports default-shared to My Health Record unless a patient opts out. The ADHA provider-readiness window closes on that date. Private pathology and imaging operators without compliant API or HL7/FHIR upload pathways will be out of compliance on day one.

The Productivity Commission's Report on Government Services 2026 update, covered by the AFR on 17 April, surfaced continued variation in hospital-acquired complication rates and funding-model performance across states and territories. The update reinforces existing signals that activity-based funding has not closed the safety gap and that capital-efficiency pressure on public hospitals is rising.

Following the PBAC's September 2025 recommendation, BMS's Opdivo® (nivolumab) and Yervoy® (ipilimumab) moved to a single multi-indication PBS listing on 1 March 2026 — the first such listing in Australia. The broad listing consolidates 17 tumour-specific listings (melanoma, NSCLC, RCC, head & neck, gastro-oesophageal, urothelial, and others) and removes the once-in-a-lifetime restriction for advanced/metastatic cancers. An estimated 5,000+ Australians per year are expected to benefit, with per-course savings of around $100,000; patients pay no more than $25 per script. Health Minister Mark Butler described the listing as a "landmark extension"; the RACGP flagged rare-cancer access as the standout benefit.

Health Minister Butler announced on 17 April a suite of PBS listings for lung and bladder cancer therapies, continuing the March multi-indication immuno-oncology reform through tumour-specific expansions. Detail on agents and effective dates published via the PBS Schedule updates for May 2026.

The US FDA approved Eli Lilly's orforglipron (brand name Foundayo) on 1 April 2026 as the first oral small-molecule GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight with weight-related comorbidities. As an oral daily tablet (not an injection, not a peptide), orforglipron removes cold-chain and sharps-waste constraints, simplifies adherence, and materially changes the unit-economics of GLP-1 supply. AU regulatory submission is expected through 2026.